Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 1053-1059

  Hershman, Dawn L ^a,b   Tsui, Jennifer ^b   Wright, Jason D ^a,b   Coromilas, Ellie J ^a   Tsai, Wei Yann ^b   Neugut, Alfred I ^a,b  

^a Herbert Irving Comprehensive Cancer Center College of Physic and Surg ^*  (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER HORMONE THERAPY; COMORBIDITY; DISEASE SEVERITY; EARLY CANCER; EDUCATION; FEMALE; HOUSEHOLD NET WORTH; HUMAN; INCOME; INSURANCE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICARE; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; AGED; BREAST NEOPLASMS; DRUG COST; ETHNOLOGY; HEALTH DISPARITY; HEALTH INSURANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; SOCIAL CLASS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

HORMONE;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMORBIDITY; DRUG COSTS; FEMALE; HEALTH STATUS DISPARITIES; HORMONES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; KAPLAN-MEIER ESTIMATE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SOCIAL CLASS; TREATMENT OUTCOME; UNITED STATES;

EID: 84927137101     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.3062     Document Type: Article

References (48)

1. Haynes RB, Ackloo E, Sahota N, et al: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2:CD000011, 2008
2. Banning M: A review of interventions used to improve adherence to medication in older people. Int J Nurs Stud 46:1505-1515, 2009
3. Conn VS, Hafdahl AR, Cooper PS, et al: Interventions to improve medication adherence among older adults: Meta-analysis of adherence outcomes among randomized controlled trials. Gerontologist 49:447-462, 2009
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
5. Visvanathan K, Hurley P, Bantug E, et al: Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:2942-2962, 2013
6. Kimmick G, Anderson R, Camacho F, et al: Adjuvant hormonal therapy use among insured, lowincome women with breast cancer. J Clin Oncol 27:3445-3451, 2009
7. Ziller V, Kalder M, Albert US, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436, 2009
8. Partridge AH, LaFountain A, Mayer E, et al: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562, 2008
9. Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology 71:1-9, 2006
10. Lash TL, Fox MP, Westrup JL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220, 2006
11. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
12. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008
13. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996
14. Yood MU, Owusu C, Buist DS, et al: Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206:66-75, 2008
15. Bryant J, Fisher B, Dignam J: Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 30:56-61, 2001
16. Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004
17. Grunfeld EA, Hunter MS, Sikka P, et al: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97-102, 2005
18. Silber JH, Rosenbaum PR, Clark AS, et al: Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389-397, 2013
19. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
20. Hershman D, Tsui J, Meyer J, et al: Change from brand to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. J Natl Cancer Inst 106:11, 2014
21. American Cancer Society: Breast Cancer Facts and Figures, 2011-2012. Atlanta, GA, American Cancer Society, 2011
22. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA, American Cancer Society, 2010
23. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334-357, 2002
24. Hassett MJ, Griggs JJ: Disparities in breast cancer adjuvant chemotherapy: Moving beyond yes or no. J Clin Oncol 27:2120-2121, 2009
25. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006
26. Hershman DL, Wang X, McBride R, et al: Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99:313-321, 2006
27. Hershman DL, Wang X, McBride R, et al: Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65:1353-1360, 2006
28. Pollack CE, Cubbin C, Sania A, et al: Do wealth disparities contribute to health disparities within racial/ethnic groups? J Epidemiol Community Health 67:439-445, 2013
29. Dang DK, Pont JM, Portnoy MA: Episode treatment groups: An illness classification and episode building system-Part I. Med Interface 9:118-122, 1996
30. Dang DK, Pont JM, Portmoy MA: Episode treatment groups: An illness classification and episode building system-Part II. Med Interface 9:122-128, 1996
31. Hess LM, Raebel MA, Conner DA, et al: Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann Pharmacother 40: 1280-1288, 2006
32. Ubel PA, Abernethy AP, Zafar SY: Full disclosure: Out-of-pocket costs as side effects. N Engl J Med 369:1484-1486, 2013
33. Shankaran V, Jolly S, Blough D, et al: Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: A population-based exploratory analysis. J Clin Oncol 30:1608-1614, 2012
34. Ramsey S, Blough D, Kirchhoff A, et al: Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
35. Kent EE, Forsythe LP, Yabroff KR, et al: Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119:3710-3717, 2013
36. Weaver KE, Rowland JH, Bellizzi KM, et al: Forgoing medical care because of cost: Assessing disparities in healthcare access among cancer survivors living in the United States. Cancer 116:3493-3504, 2010
37. Zhang Y, Baik SH, Lave JR: Effects of Medicare Part D coverage gap on medication adherence. Am J Manag Care 19:e214-e224, 2013
38. Stuart B, Davidoff A, Erten M, et al: How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction. Health Serv Res 48:1960-1977, 2013
39. Williams BA, Lindquist K, Sudore RL, et al: Screening mammography in older women: Effect of wealth and prognosis. Arch Intern Med 168:514-520, 2008
40. Silveira MJ, Kabeto MU, Langa KM: Net worth predicts symptom burden at the end of life. J Palliat Med 8:827-837, 2005
41. Pollack CE, Chideya S, Cubbin C, et al: Should health studies measure wealth? A systematic review. Am J Prev Med 33:250-264, 2007
42. Allin S, Masseria C, Mossialos E: Measuring socioeconomic differences in use of health care services by wealth versus by income. Am J Public Health 99:1849-1855, 2009
43. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113: 5401-5411, 2009
44. Darkow T, Henk HJ, Thomas SK, et al: Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25: 481-496, 2007
45. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
46. Hawwa AF, Millership JS, Collier PS, et al: The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia: An exploratory study. Eur J Clin Pharmacol 65:1105-1112, 2009
47. Partridge AH, Archer L, Kornblith AB, et al: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 28:2418-2422, 2010
48. Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66, 2009